Keyphrases
In Cancer
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
Cancer Patients
100%
Sorafenib
100%
Hypertension Risk
100%
Hypertension
72%
Confidence Interval
27%
Relative Risk
27%
High Risk
18%
Renal Cell Carcinoma
18%
Phase II Trial
18%
Clinical Trials
9%
Subgroup Analysis
9%
Randomized Trial
9%
Cancer Types
9%
Medline Database
9%
Meeting Abstracts
9%
Severe Hypertension
9%
American Society of Clinical Oncology
9%
Multikinase Inhibitor
9%
Common Terminology Criteria for Adverse Events (CTCAE)
9%
Online Database
9%
Sorafenib Treatment
9%
Concomitant Chemotherapy
9%
Medicine and Dentistry
Malignant Neoplasm
100%
Meta-Analysis
100%
Systematic Review
100%
Sorafenib
100%
Clear Cell Renal Cell Carcinoma
16%
Adverse Event
8%
Clinical Trial
8%
Immunotherapy
8%
Subgroup Analysis
8%
Clinical Oncology
8%
Phosphotransferase Inhibitor
8%
Chemotherapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Sorafenib
100%
Renal Cell Carcinoma
16%
Adverse Event
8%
Immunotherapy
8%
Clinical Trial
8%
Chemotherapy
8%
Phosphotransferase Inhibitor
8%
Immunology and Microbiology
Sorafenib
100%
Carcinoma Cell
16%
Immunotherapy
8%
Medline
8%
Nomenclature
8%